Jane Street’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jane Street’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$492K	Buy	+26,400	New	+$437K	﹤0.01%	8072
2025 Q3	–	Sell	-19,300	Closed	-$911K	–	11397
2025 Q2	$911K	Sell	19,300 -5,700	-23%	-$232K	﹤0.01%	5788
2025 Q1	$977K	Buy	25,000 +18,900	+310%	+$814K	﹤0.01%	5613
2024 Q4	$330K	Hold	6,100	–	–	﹤0.01%	7578
2024 Q3	$308K	Sell	6,100 -12,600	-67%	-$590K	﹤0.01%	7994
2024 Q2	$822K	Sell	18,700 -32,900	-64%	-$1.39M	﹤0.01%	6156
2024 Q1	$2.59M	Sell	51,600 -3,800	-7%	-$206K	﹤0.01%	3655
2023 Q4	$3.35M	Buy	55,400 +5,600	+11%	+$289K	﹤0.01%	3458
2023 Q3	$2.84M	Buy	+49,800	New	+$2.75M	﹤0.01%	3455

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's MLTX Position: Q1 2026 in Review

Jane Street reduced its MoonLake Immunotherapeutics (MLTX) stake by 73% in Q1 2026, selling an estimated $20.3M and leaving 453,625 shares worth $8.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2751.

Jane Street first reported a position in MLTX in Q1 2022 and has held it in 12 quarters since. The position peaked at $22.2M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Jane Street held 453,625 shares of MoonLake Immunotherapeutics worth $8.46M as of Q1 2026.
Jane Street sold 1,228,523 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $20.3M.
MoonLake Immunotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2751 holding.
Jane Street first reported a position in MoonLake Immunotherapeutics in Q1 2022 and has held it in 12 quarters since.
Jane Street's MoonLake Immunotherapeutics position peaked at $22.2M in Q4 2025.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.